Lukas SVEIKATA

Dr. Lukas SVEIKATA

Geneva University Hospitals and Faculty of Medicine, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Current Opinion in Neurology
Verified
Journal Article
Open access
MZMaria Clara Zanon Zotin
Maria Clara Zanon Zotin
Lukas SVEIKATALukas SVEIKATA
Lukas SVEIKATA
AVAnand Viswanathan
Anand Viswanathan
PYPinar Yilmaz
Pinar Yilmaz
Purpose of review: We present recent developments in the field of small vessel disease (SVD)-related vascular cognitive impairment, including pathological mechanisms, updated diagnostic criteria, cognitive profile, neuroimaging markers and risk factors. We further address available management and therapeutic strategies. Recent findings: Vascular and neurodegenerative pathologies often co-occur and share similar risk factors. The updated consensus criteria aim to standardize vascular cognitive impairment (VCI) diagnosis, relying strongly on cognitive profile and MRI findings. Aggressive blood pressure control and multidomain lifestyle interventions are associated with decreased risk of cognitive impairment, but disease-modifying treatments are still lacking. Recent research has led to a better understanding of mechanisms leading to SVD-related cognitive decline, such as blood-brain barrier dysfunction, reduced cerebrovascular reactivity and impaired perivascular clearance. Summary: SVD is the leading cause of VCI and is associated with substantial morbidity. Tackling cardiovascular risk factors is currently the most effective approach to prevent cognitive decline in the elderly. Advanced imaging techniques provide tools for early diagnosis and may play an important role as surrogate markers for cognitive endpoints in clinical trials. Designing and testing disease-modifying interventions for VCI remains a key priority in healthcare.

1 March 2023 in Radiology
Verified
Journal Article
Closed access
MZMaria Clara Zanon Zotin
Maria Clara Zanon Zotin
PYPinar Yilmaz
Pinar Yilmaz
Lukas SVEIKATALukas SVEIKATA
Lukas SVEIKATA
DSDorothee Schoemaker
Dorothee Schoemaker
SVSusanne J. van Veluw
Susanne J. van Veluw
AVAnand Viswanathan
Anand Viswanathan
A leading cause of white matter (WM) injury in older individuals is cerebral small vessel disease (SVD). Cerebral SVD is the most prevalent vascular contributor to cognitive impairment and dementia. Therapeutic progress for cerebral SVD and other WM disorders depends on the development and validation of neuroimaging markers suitable as outcome measures in future interventional trials. Diffusion-tensor imaging (DTI) is one of the best-suited MRI techniques for assessing the extent of WM damage in the brain. But the optimal method to analyze individual DTI data remains hindered by labor-intensive and time-consuming processes. Peak width of skeletonized mean diffusivity (PSMD), a recently developed fast, fully automated DTI marker, was designed to quantify the WM damage secondary to cerebral SVD and reflect related cognitive impairment. Despite its promising results, knowledge about PSMD is still limited in the radiologic community. This focused review provides an overview of the technical details of PSMD while synthesizing the available data on its clinical and neuroimaging associations. From a critical expert viewpoint, the authors discuss the limitations of PSMD and its current validation status as a neuroimaging marker for vascular cognitive impairment. Finally, they point out the gaps to be addressed to further advance the field.

1 January 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
Lukas SVEIKATALukas SVEIKATA
Lukas SVEIKATA
ACAndreas Charidimou
Andreas Charidimou
AVAnand Viswanathan
Anand Viswanathan
We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

7 October 2021 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
Lukas SVEIKATALukas SVEIKATA
Lukas SVEIKATA
LVLana Vasung
Lana Vasung
ARAmir El Rahal
Amir El Rahal
ABAndrea Bartoli
Andrea Bartoli
MBMartin Bretzner
Martin Bretzner
BLBéatrice Leemann
Béatrice Leemann
Syndrome of the trephined (SoT) is an underrecognized complication after decompressive craniectomy. We aimed to investigate SoT incidence, clinical spectrum, risk factors, and the impact of the cranioplasty on neurologic recovery. Patients undergoing a large craniectomy (> 80 cm2) and cranioplasty were prospectively evaluated using modified Rankin score (mRS), cognitive (attention/processing speed, executive function, language, visuospatial), motor (Motricity Index, Jamar dynamometer, postural score, gait assessment), and radiologic evaluation within four days before and after a cranioplasty. The primary outcome was SoT, diagnosed when a neurologic improvement was observed after the cranioplasty. The secondary outcome was a good neurologic outcome (mRS 0–3) 4 days and 90 days after the cranioplasty. Logistic regression models were used to evaluate the risk factors for SoT and the impact of cranioplasty timing on neurologic recovery. We enrolled 40 patients with a large craniectomy; 26 (65%) developed SoT and improved after the cranioplasty. Brain trauma, hemorrhagic lesions, and shifting of brain structures were associated with SoT. After cranioplasty, a shift towards a good outcome was observed within 4 days (p = 0.025) and persisted at 90 days (p = 0.005). Increasing delay to cranioplasty was associated with decreased odds of improvement when adjusting for age and baseline disability (odds ratio 0.96; 95% CI, 0.93–0.99, p = 0.012). In conclusion, SoT is frequent after craniectomy and interferes with neurologic recovery. High suspicion of SoT should be exercised in patients who fail to progress or have a previous trauma, hemorrhage, or shifting of brain structures. Performing the cranioplasty earlier was associated with improved and quantifiable neurologic recovery.

31 January 2025 in Journal Of Neuroradiology
Verified
Journal Article
Open access
DBDaniele Botta
Daniele Botta
IHIoana Hutuca
Ioana Hutuca
EGElyas El Ghoul
Elyas El Ghoul
Lukas SVEIKATALukas SVEIKATA
Lukas SVEIKATA
FAFrédéric Assal
Frédéric Assal
FKFelix T. Kurz
Felix T. Kurz
The discovery of the glymphatic system has revolutionized our understanding of brain physiology, particularly in waste clearance and fluid dynamics within the central nervous system. This pathway, essential for nutrient distribution and waste removal, operates predominantly during sleep and has been implicated in neurodegenerative diseases like Alzheimer's and Parkinson's. Recent advances in non-invasive MRI techniques, including diffusion tensor imaging along the perivascular space (DTI-ALPS), perivascular space (PVS) analysis, and free water (FW) indices, have improved our ability to study glymphatic function and its alterations in disease states. This review discusses the glymphatic system's ultrastructure, physiology, and the latest imaging methods to assess this critical pathway. We highlight how these non-invasive MRI techniques can enhance the understanding of glymphatic function in health and disease, with a focus on neurodegenerative conditions. By integrating insights from current research, this review underscores the diagnostic and therapeutic implications of glymphatic dysfunction. Understanding these mechanisms can pave the way for novel strategies to enhance waste clearance and improve neurological health, offering potential benefits for early diagnosis and intervention in neurodegenerative diseases.

Verified
Journal Article
Open access
PDF file
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
Mirjam R HeldnerMirjam R Heldner
Mirjam R Heldner
KAKristina Adorjan
Kristina Adorjan
EAEmiliano Albanese
Emiliano Albanese
GAGilles Allali
Gilles Allali
LRLuca Remonda
Luca Remonda
The brain and its health are essential for our (physical mental, social, and spiritual) wellbeing, for being able to realize our potential as individuals, and also for a fair, well-functioning, and productive society. However, today the world is facing a healthcare crisis related to the very high (and increasing) burden of brain disorders. As a response to this crisis, the “Swiss Brain Health Plan” (SBHP) was conceptualized in the context of other initiatives launched to value, promote, and protect brain health over the entire life course. In the first section of this position paper, the following fundamental considerations of the SBHP are discussed: (1) the high (and increasing) burden of brain disorders in terms of prevalence (>50% of the population suffers from a brain disorder), disability, mortality, and costs; (2) the prevention of brain disorders; (3) the operational definition of brain health; (4) determinants of brain health; (5) international initiatives to promote brain (including mental) health including the World Health Organization (WHO) intersectorial global action plan on epilepsy and other neurological disorders (NDs) (IGAP) and the WHO comprehensive mental health action plan. In the second section of the paper, the five strategic objectives of the SBHP, which has the vision of promoting brain health for all across the entire life course, are presented: (1) to raise awareness; (2) strengthen cross-disciplinary and interprofessional training/educational programs for healthcare professionals; (3) foster research on brain health determinants and individualized prevention of brain disorders; (4) prioritize a holistic (non-disease-specific), integrated, person-centered public health approach to promote brain health and prevent brain disorders through collaborations across scientific, health care, commercial, societal and governmental stakeholders and insurance providers; (5) support, empower, and engage patients, caregivers, and patient organizations, and reduce the stigma and discrimination related to brain disorders. In the third section of the paper, the first (2024) steps in the implementation of the SHBP, which will be officially launched in Zurich on 22 November 2023, are presented: (1) a definition of the overall organization, governance, specific targets, and action areas of the SBHP; (2) the patronage and/or co-organization of events on such specific topics as brain research (Lausanne), dementia (Geneva), stroke (Basel), neurohumanities (Bellinzona), sleep (Lugano), and psychiatry (Zurich); (3) the conduction of a new study on the global burden of brain disorders in Switzerland; (4) the launching of an international Certificate of Advanced Studies (CAS) on Brain Health at the University of Bern. In the fourth section of the paper, there is a concise executive summary of the SBHP.